Analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of Merck & Co., Inc. in a research report issued to clients and investors on Friday, January 24th. Leerink Partnrs analyst D.

Intuitive Surgical (NASDAQ:ISRG – Free Report) had its target price boosted by JPMorgan Chase & Co. from $575.00 to $675.00 ...

TNYA Stock Performance and Moving Averages. In recent trading, Tenaya Therapeutics Inc (TNYA) stock price has shown some volatility, fluctuating -12.95% over the last five trades ...

Elanco Animal Health Inc (ELAN) stock saw a modest uptick, ending the day at $12.08 which represents a slight increase of $0.02 or 0.17% from the prior close of $12.06. The stock opened at $12.1 and ...

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Castle Biosciences (CSTL – Research Report) yesterday and set a price target ...

For IDRx, Centerview Partners LLC is acting as exclusive financial advisor and Goodwin Procter LLP as legal counsel. For GSK, Leerink Partners LLC is acting as the exclusive financial advisor.